APRINOIA Therapeutics Inc. (APRI)

APRINOIA Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021
Cash & Equivalents	1.22	9.67
Cash & Cash Equivalents	1.22	9.67
Cash Growth	-87.38%	-
Receivables	-	0.16
Other Current Assets	0.59	0.43
Total Current Assets	1.81	10.26
Property, Plant & Equipment	2.15	0.51
Goodwill and Intangibles	0.15	0.32
Other Long-Term Assets	1.53	1.68
Total Long-Term Assets	3.83	2.51
Total Assets	5.64	12.77
Accounts Payable	8.89	0.43
Current Debt	3.57	0.94
Other Current Liabilities	2.72	2.99
Total Current Liabilities	15.18	4.36
Long-Term Debt	0.04	0.18
Total Long-Term Liabilities	0.04	0.18
Total Liabilities	15.22	4.54
Total Debt	3.61	1.12
Debt Growth	223.75%	-
Retained Earnings	-90.64	-62.41
Comprehensive Income	-0.97	-0.49
Shareholders' Equity	-75.45	-48.69
Net Cash / Debt	-2.39	8.56
Working Capital	-13.36	5.89

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).